SCIENTIFIC ADVISORY BOARD

We can draw on over 150 years of experience in Life Science, cell therapy and diagnostics thanks to five internationally renowned industry experts. Our well experienced team of high-calibre professional advisors are bringing new expertise to lino Biotech. Our Advisory Board includes the following distinguished biotechnology, bioprocessing and medical technology industry experts:Read the full press release here.

Dr. Christof Fattinger, invented the principle of Focal Molography and developed its theoretical foundations. From 2014 to 2020, Dr. Fattinger led the development of Focal Molography in collaboration with Prof. Janos Vörös, ETH Zürich, and several docs and postdocs in his group.

CF studied physics at ETH Zürich and received a postdoctoral fellowship from IBM, T.J.Watson Research Center, NY. His work at IBM, in collaboration Daniel R. Grischkowsky, led to an optoelectronic technique for generating diffraction-limited beams of terahertz electromagnetic pulses. He co-authored the most cited scientific article in the field of terahertz spectroscopy.

From 1989 – 2019 Dr. Christof Fattinger was working in pharmaceutical industry at the Roche Innovation Center in Basel. In 2010, CF was awarded the status of Distinguished Scientist, the highest accolade for a Roche researcher. CF brings extraordinary scientific/technical merits to the discovery and realization of new methods for the analysis and study of biomolecular interactions.

Dr. Christof Fattinger is a Member of the Swiss Academy of Engineering Sciences SATW.

Dr. Patrik Forrer

Following his strong quest for disruptive innovations, Patrik developed the concept for the designed ankyrin repeat protein (DARPin) technology at University of Zurich. Based on this technology, he co-founded Molecular Partners AG (SIX: MOLN) and Athebio AG, where he currently serves as CEO. He was involved in most aspects of setting up a biotech company from its beginnings, including the preclinical development of DARPins bringing them successfully into the clinic, heading the intellectual property department, deal negotiations with big pharma and the IPO of Molecular Partners in 2014. Further, he serves Pharmabiome AG as a Board member. All these distinct experiences give him a deep strategic and operational understanding of the biotech business.

Dr. Klaus-Dieter Langner

Klaus-D. Langner, Ph. D., has an extensive background in life sciences including Biotech, Small Molecules and MedTech. He held various management positions at Behring/Hoechst and Grünenthal GmbH, where he spend 8 years in executive positions, 3 years as Chief Operating Officer of Grünenthal Innovation and 5 years as Chief Scientific Officer of Grünenthal GmbH, Member of the Executive Board. Educated as Molecular Biologist at University of Cologne (Ph. D. in Genetics).

 

Marius Rosenberg is Managing Director of the Exzellenz Start-up Center at RWTH Aachen University and Co-Founder and former Managing Director of Adhesys Medical, a high-tech medical device startup.
Marius has co-founded other tech startups and is a business angel investor in the high-tech and life science space. He is a Member of the Supervisory Board of Bionorica SE as well as Member of the Advisory Board of RWTH Innovation GmbH.
Prior to that, Marius has worked as a strategy consultant for The Boston Consulting Group. He studied Business Administration at the WHU – Otto Beisheim School of Management and worked as a PhD candidate at the RWTH Center for Entrepreneurship.

Dr. Klaus-Peter Stengele

Dr. Klaus-Peter Stengele, LifeScience and Diagnostics Consultant and Specialist in R&D and Innovation Management with an emphasis on a small company environment. With a PhD in Chemistry, his speciality lies in nucleic acids, peptides and microarrays. As former Senior Director Technology Innovation at Roche Diagnostics he was involved in all aspects of early development of assay technologies and reagents. His ambitions center around precision medicine and democratizing diagnostics.